Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease

This study has been terminated.
(Voluntary halt of further dosing due to an FDA Clinical Hold issued in relation to Dynavax study DV2-HBV-10)
Sponsor:
Information provided by (Responsible Party):
Dynavax Technologies Corporation
ClinicalTrials.gov Identifier:
NCT00498212
First received: July 5, 2007
Last updated: June 16, 2014
Last verified: June 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2008
  Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: June 16, 2014